Moderna's mRNA flu shot earns FDA approval after rollercoaster review
Moderna's mRNA-based flu vaccine has received FDA approval for adults aged 50 and older following a unanimous advisory vote. The approval process faced significant political friction due to the current administration's stance on mRNA technology.
Why it matters
This marks a milestone for mRNA technology beyond COVID-19, despite ongoing political controversy surrounding vaccine policy.
Approved Moderna’s mRNA flu shot earns FDA approval after rollercoaster review Moderna’s new flu vaccine, mFLUSIVA, is approved for all adults ages 50 and up.
58 Credit: DeFodi Images Credit: DeFodi Images Text settings Story text Size Small Standard Large Width * Standard Wide Links Standard Orange * Subscribers only Learn more Minimize to nav Despite significant drama from Trump officials this year, the Food and Drug Administration has for the first time approved a flu vaccine that uses mRNA technology.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in